Digestive Diseases and Sciences

, Volume 54, Issue 6, pp 1178–1183 | Cite as

Hepatic Venous Pressure Gradient: Worth Another Look?

  • Sameer Parikh


Portal hypertension is one of the most important complications of chronic liver disease and accounts for significant morbidity and mortality. Measurement of the hepatic venous pressure gradient (HVPG) is a simple, invasive, and reproducible method of assessing portal venous pressure. Measurement of HVPG provides the clinician an estimate of the degree of intrahepatic portal flow resistance, guides therapy for variceal bleeding (primary and secondary prophylaxis), assesses feasibility of resection in patients with hepatocellular cancer, and predicts response to therapy of patients with chronic hepatitis C. Achieving hemodynamic targets of reducing the HVPG to <10 mmHg or a 20% reduction from baseline virtually eliminates complications related to portal hypertension from chronic liver disease. This review explores the role of HVPG measurement in the contemporary treatment of patients with cirrhosis and portal hypertension.


Cirrhosis Portal hypertension Variceal bleeding Liver function tests 



I would like to thank Ms. Yvette Pinales for her help in preparing this manuscript.


  1. 1.
    Myers J, Taylor W. An estimation of portal venous pressure by occlusive catheterization of a hepatic venule. J Clin Invest. 1951;30:662–663.Google Scholar
  2. 2.
    Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006;26(4):348–362. doi: 10.1055/s-2006-951603.PubMedCrossRefGoogle Scholar
  3. 3.
    Perello A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30(6):1393–1397.PubMedCrossRefGoogle Scholar
  4. 4.
    Lin HC, Tsai YT, Lee FY, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol. 1989;9(3):326–330. doi: 10.1016/0168-8278(89)90141-4.PubMedCrossRefGoogle Scholar
  5. 5.
    Boyer TD, Triger DR, Horisawa M, Redeker AG, Reynolds TB. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology. 1977;72(4 Pt 1):584–589.PubMedGoogle Scholar
  6. 6.
    Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99(5):1401–1407.PubMedGoogle Scholar
  7. 7.
    Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346(8982):1056–1059. doi: 10.1016/S0140-6736(95)91740-3.PubMedCrossRefGoogle Scholar
  8. 8.
    Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;32(5):930–934.PubMedCrossRefGoogle Scholar
  9. 9.
    Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101(3):506–512. doi: 10.1111/j.1572-0241.2006.00453.x.PubMedCrossRefGoogle Scholar
  10. 10.
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902–908.PubMedCrossRefGoogle Scholar
  11. 11.
    Villanueva C, Lopez-Balaguer JM, Aracil C, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40(5):757–765. doi: 10.1016/j.jhep.2004.01.017.PubMedCrossRefGoogle Scholar
  12. 12.
    Escorsell A, Bordas JM, Castaneda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 2003;31(5):1061–1067.CrossRefGoogle Scholar
  13. 13.
    Bureau C, Peron JM, Alric L, et al. “A La Carte” treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36(6):1361–1366.PubMedGoogle Scholar
  14. 14.
    Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334(25):1624–1629. doi: 10.1056/NEJM199606203342502.PubMedCrossRefGoogle Scholar
  15. 15.
    Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345(9):647–655. doi: 10.1056/NEJMoa003223.PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37(6):1260–1266.PubMedCrossRefGoogle Scholar
  17. 17.
    Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology. 1986;6(1):101–106.PubMedCrossRefGoogle Scholar
  18. 18.
    de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–176. doi: 10.1016/j.jhep.2005.05.009.PubMedCrossRefGoogle Scholar
  19. 19.
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–938.PubMedCrossRefGoogle Scholar
  20. 20.
    D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131(5):1611–1624. doi: 10.1053/j.gastro.2006.09.013.PubMedCrossRefGoogle Scholar
  21. 21.
    Rincon D, Lo Iacono O, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther. 2007;25(7):841–848.PubMedCrossRefGoogle Scholar
  22. 22.
    Burroughs AK, Groszmann R, Bosch J, et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut. 2002;50(3):425–427. doi: 10.1136/gut.50.3.425.PubMedCrossRefGoogle Scholar
  23. 23.
    Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):932–937. doi: 10.1016/j.cgh.2007.02.022.PubMedCrossRefGoogle Scholar
  24. 24.
    Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol. 2006;101(10):2269–2274. doi: 10.1111/j.1572-0241.2006.00743.x.PubMedCrossRefGoogle Scholar
  25. 25.
    Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132(5):1746–1756. doi: 10.1053/j.gastro.2007.03.041.PubMedCrossRefGoogle Scholar
  26. 26.
    Samonakis DN, Cholongitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl. 2007;13(9):1305–1311. doi: 10.1002/lt.21227.PubMedCrossRefGoogle Scholar
  27. 27.
    Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43(3):492–499.PubMedCrossRefGoogle Scholar
  28. 28.
    Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111(4):1018–1022. doi: 10.1016/S0016-5085(96)70070-7.PubMedCrossRefGoogle Scholar
  29. 29.
    Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. Portal hypertension: contraindication to liver surgery? World J Surg. 2006;30(6):992–999. doi: 10.1007/s00268-005-0524-9.PubMedCrossRefGoogle Scholar
  30. 30.
    Tandon P, Garcia-Tsao G. Portal hypertension and hepatocellular carcinoma: prognosis and beyond. Clin Gastroenterol Hepatol. 2006;4(11):1318–1319. doi: 10.1016/j.cgh.2006.09.009.PubMedCrossRefGoogle Scholar
  31. 31.
    Wang YW, Huo TI, Yang YY, et al. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol. 2007;41(7):706–712. doi: 10.1097/MCG.0b013e31802dabb3.PubMedCrossRefGoogle Scholar
  32. 32.
    Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–488. doi: 10.1053/j.gastro.2007.05.024.PubMedCrossRefGoogle Scholar
  33. 33.
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39(2):280–282.PubMedCrossRefGoogle Scholar
  34. 34.
    Boyer TD. Wedged hepatic vein pressure (WHVP): ready for prime time. Hepatology. 2006;43(3):405–406.PubMedCrossRefGoogle Scholar
  35. 35.
    Hicken BL, Sharara AI, Abrams GA, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther. 2003;17(1):145–153. doi: 10.1046/j.1365-2036.2003.01391.x.PubMedCrossRefGoogle Scholar
  36. 36.
    Targownik LE, Spiegel BM, Dulai GS, Karsan HA, Gralnek IM. The cost-effectiveness of hepatic venous pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. Am J Gastroenterol. 2004;99(7):1306–1315. doi: 10.1111/j.1572-0241.2004.30754.x.PubMedCrossRefGoogle Scholar
  37. 37.
    Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45(5):1290–1297.PubMedCrossRefGoogle Scholar
  38. 38.
    Spahr L, Giostra E, Morard I, Mentha G, Hadengue A. Perendoscopic variceal pressure measurement: a reliable estimation of portal pressure in patients with cirrhosis? Gastroenterol Clin Biol. 2006;30(8–9):1012–1018. doi: 10.1016/S0399-8320(06)73376-0.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of MedicineBaylor College of MedicineHoustonUSA

Personalised recommendations